- Home
- LIND vs ETNB Comparison
LIND vs ETNB Comparison
Compare LIND & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIND
- ETNB
- Stock Information
- Founded
- LIND 1979
- ETNB 2018
- Country
- LIND United States
- ETNB United States
- Employees
- LIND N/A
- ETNB N/A
- Industry
- LIND Transportation Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- LIND Consumer Discretionary
- ETNB Health Care
- Exchange
- LIND Nasdaq
- ETNB Nasdaq
- Market Cap
- LIND 742.0M
- ETNB 1.2B
- IPO Year
- LIND N/A
- ETNB 2019
- Fundamental
- Price
- LIND $9.55
- ETNB $8.13
- Analyst Decision
- LIND Strong Buy
- ETNB Strong Buy
- Analyst Count
- LIND 4
- ETNB 9
- Target Price
- LIND $14.25
- ETNB $30.29
- AVG Volume (30 Days)
- LIND 382.3K
- ETNB 1.6M
- Earning Date
- LIND 04-29-2025
- ETNB 05-08-2025
- Dividend Yield
- LIND N/A
- ETNB N/A
- EPS Growth
- LIND N/A
- ETNB N/A
- EPS
- LIND N/A
- ETNB N/A
- Revenue
- LIND $644,727,000.00
- ETNB N/A
- Revenue This Year
- LIND $10.60
- ETNB N/A
- Revenue Next Year
- LIND $11.92
- ETNB N/A
- P/E Ratio
- LIND N/A
- ETNB N/A
- Revenue Growth
- LIND 13.20
- ETNB N/A
- 52 Week Low
- LIND $6.35
- ETNB $5.99
- 52 Week High
- LIND $14.34
- ETNB $13.71
- Technical
- Relative Strength Index (RSI)
- LIND 34.98
- ETNB 47.39
- Support Level
- LIND $10.04
- ETNB $6.88
- Resistance Level
- LIND $11.54
- ETNB $9.40
- Average True Range (ATR)
- LIND 0.80
- ETNB 0.63
- MACD
- LIND -0.10
- ETNB -0.19
- Stochastic Oscillator
- LIND 27.18
- ETNB 42.37
About LIND Lindblad Expeditions Holdings Inc.
Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of nine owned expedition ships and five seasonal charter vessels under the Lindblad brand.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).